Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. Rheumatology and therapy Genovese, M. C., Greenwald, M. W., Gutierrez-Urena, S. R., Cardiel, M. H., Poiley, J. E., Zubrzycka-Sienkiewicz, A., Codding, C. E., Wang, A., He, W., Amos, R., Vinueza, R., Wang, X., Garg, J. P., Kivitz, A. J. 2019


INTRODUCTION: Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phaseIIbtrials investigated the long-term safety and effectiveness of peficitinib.METHODS: All eligible patients with moderate-to-severe RA including patients in the placebo group who participated in one of two global phase IIb trials ('with methotrexate' or 'without methotrexate') were included in this 2-year open-label extension study and were converted to peficitinib100mg once daily. The primary objective was to evaluate an additional 2years of safety by assessing treatment-emergent adverse events (AEs) and clinical laboratory evaluations for 105weeks. Evaluation of an additional 2years of effectiveness using American College of Rheumatology (ACR) 20/50/70 responses was the exploratory objective.RESULTS: Overall, 611 patients were enrolled in the extension study: 319 (52.2%) patients completed the study and 292 (48%) discontinued treatment, including for withdrawal of patient consent (n=96), failure to achieve low disease activity (n=62), and AE not including death (n=41). AEs were reported in 463(76%) patients. The most common AEs (per 100 patient-years) were upper respiratory tract infections (9.9) and urinary tract infections (7.2). Serious AEs were reported in 80 (13%) patients, with incidences per 100 patient-years of serious infections 2.7, herpes zoster 1.5 (including one herpes zoster ophthalmic), and malignancies 0.6 (most frequently basal cell carcinoma). At week 105, 269 (44%) patients demonstrated an ACR20 response relative to their respective phaseIIb trial baselines.CONCLUSION: Among 319 patients who completed this 2-year extension of two global phase IIb studies, peficitinib 100mg once daily demonstrated a stable safety profile and sustained effectiveness in patients with moderate-to-severe RA.TRIAL REGISTRATION: identifier, NCT01711814. Registered 19 October 2012.FUNDING: Astellas Pharma Global Development, Inc.

View details for DOI 10.1007/s40744-019-00167-6

View details for PubMedID 31410787